Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

<strong>Background<br></strong> The 4-component capsular group B meningococcal vaccine (4CMenB) was licensed as a 4-dose infant schedule but introduced into the United Kingdom as 3 doses at 2, 4, and 12 months of age. We describe the immunogenicity and reactogenicity of the 2 + 1 s...

Descrición completa

Detalles Bibliográficos
Main Authors: Valente Pinto, M, O'Connor, D, Galal, U, Clutterbuck, EA, Robinson, H, Plested, E, Bibi, S, Camara Pellisso, S, Hughes, H, Kerridge, S, Mujadidi, YF, Findlow, H, Borrow, R, Snape, MD, Pollard, AJ
Formato: Journal article
Idioma:English
Publicado: Oxford University Press 2020

Títulos similares

Títulos similares